CCND2 and neoplasm: McCullough et al. later identified, in 2017, an association between pre-diagnostic RPA and all-cause mortality, whereby all-cause mortality was decreased only in recreationally physically active women with methylated promoters of CCND2 (HR 0.56, 95% CI 0.32–0.99), APC (HR 0.60, 95% CI 0.40–0.80), HIN (HR 0.55, 95% CI 0.38–0.80), and TWIST1 (HR 0.28, 95% CI 0.14–0.56) in tumours, but not among those with unmethylated tumours, with a significant interaction (p < 0.05) [47].